tiprankstipranks
Trending News
More News >
Tonix Pharma (TNXP)
NASDAQ:TNXP
Advertisement

Tonix Pharma (TNXP) AI Stock Analysis

Compare
4,772 Followers

Top Page

TNXP

Tonix Pharma

(NASDAQ:TNXP)

Rating:55Neutral
Price Target:
$40.00
▲(2.54%Upside)
The score is primarily driven by positive corporate events, which enhance market positioning. However, profitability challenges and unattractive valuation metrics weigh down the overall score.

Tonix Pharma (TNXP) vs. SPDR S&P 500 ETF (SPY)

Tonix Pharma Business Overview & Revenue Model

Company DescriptionTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
How the Company Makes MoneyTonix Pharmaceuticals generates revenue primarily through the development and commercialization of its pharmaceutical products. The company aims to bring its drugs to market following successful clinical trials and regulatory approvals, at which point revenues are expected to be derived from product sales. Key revenue streams for the company include potential partnerships and collaborations with other pharmaceutical companies, licensing agreements, and government contracts for research and development. Tonix’s earnings are significantly influenced by the successful progression of its drug candidates through the clinical trial phases and obtaining necessary regulatory approvals to market its products.

Tonix Pharma Financial Statement Overview

Summary
Tonix Pharma is in a growth phase with significant revenue increase, but faces profitability challenges. The strong equity base and low financial leverage are positives, but ongoing net losses and reliance on external funding for cash flow present risks.
Income Statement
40
Negative
Tonix Pharma has shown substantial revenue growth from prior years, with total revenue increasing significantly from $0 to $10.09 million in 2024. However, profitability remains a challenge as indicated by negative EBIT and EBITDA margins. The net profit margin is nonexistent due to zero net income, suggesting the company is still in a heavy investment phase, typical for the biotechnology industry.
Balance Sheet
55
Neutral
The company's balance sheet shows a healthy equity base with a debt-to-equity ratio of approximately 0.06, indicating low financial leverage. The equity ratio is strong at 85.7%, reflecting a robust capital structure. However, consistent net losses over the years suggest potential pressures on financial sustainability if cash reserves dwindle without profitability improvements.
Cash Flow
50
Neutral
Cash flow analysis reveals a negative free cash flow, though the company has improved its operating cash flow situation compared to previous years. The significant financing cash flow indicates reliance on external funding to support operations. The cash flow to net income ratios are not meaningful due to the lack of net income.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.09M7.77M9.03M0.002.91M
Gross Profit2.33M3.03M8.03M-62.86M-30.57M
EBITDA-74.94M-114.09M-110.84M-92.26M-50.48M
Net Income-130.04M-116.66M-116.88M-92.29M-52.17M
Balance Sheet
Total Assets162.89M154.46M225.69M240.90M98.18M
Cash, Cash Equivalents and Short-Term Investments98.78M24.95M120.23M178.66M77.07M
Total Debt8.12M9.81M760.00K956.00K1.31M
Total Liabilities23.33M48.93M18.51M22.18M10.54M
Stockholders Equity139.56M105.53M207.18M218.72M87.65M
Cash Flow
Free Cash Flow-61.05M-109.90M-146.20M-110.86M-57.13M
Operating Cash Flow-60.92M-102.00M-98.05M-75.56M-48.57M
Investing Cash Flow-120.00K-29.07M-48.15M-35.31M-8.56M
Financing Cash Flow134.87M36.52M87.84M212.49M123.11M

Tonix Pharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price39.01
Price Trends
50DMA
38.54
Positive
100DMA
28.90
Positive
200DMA
25.04
Positive
Market Momentum
MACD
1.17
Positive
RSI
46.37
Neutral
STOCH
8.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNXP, the sentiment is Neutral. The current price of 39.01 is below the 20-day moving average (MA) of 42.69, above the 50-day MA of 38.54, and above the 200-day MA of 25.04, indicating a neutral trend. The MACD of 1.17 indicates Positive momentum. The RSI at 46.37 is Neutral, neither overbought nor oversold. The STOCH value of 8.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNXP.

Tonix Pharma Risk Analysis

Tonix Pharma disclosed 66 risk factors in its most recent earnings report. Tonix Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tonix Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$208.12M-58.55%825.97%38.32%
56
Neutral
$210.12M-140.82%-48.37%-44.70%
55
Neutral
$277.22M-91.44%-2.04%83.49%
51
Neutral
$7.35B0.50-65.61%2.47%15.28%1.44%
50
Neutral
$375.09M-189.46%-3.24%31.00%
42
Neutral
$109.00M5.550.51%-34.58%-62.19%
34
Underperform
$157.44M-44.50%52.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TNXP
Tonix Pharma
39.01
-6.19
-13.69%
CHRS
Coherus Biosciences
0.88
-0.44
-33.33%
NKTR
Nektar Therapeutics
22.96
5.41
30.83%
CLLS
Cellectis SA
2.95
0.91
44.61%
EDIT
Editas Medicine
2.44
-2.29
-48.41%
TIL
Instil Bio
22.23
10.91
96.38%

Tonix Pharma Corporate Events

Business Operations and Strategy
Tonix Pharma Launches Move Fibro Forward Campaign
Positive
Jul 21, 2025

On July 21, 2025, Tonix Pharmaceuticals Holding Corp. announced the launch of its Move Fibro Forward campaign, aimed at raising awareness and providing support to individuals living with fibromyalgia. This initiative reflects the company’s commitment to addressing central nervous system disorders and could enhance its market positioning by highlighting its dedication to patient support and advocacy.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Tonix Pharma Plans Sales Force for TNX-102 SL
Positive
Jul 16, 2025

On July 16, 2025, Tonix Pharmaceuticals announced plans to establish a sales force of 70 to 90 representatives for its TNX-102 SL product candidate, contingent upon FDA approval. This strategic move aims to enhance the company’s market position and operational capabilities in the fibromyalgia treatment sector.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Product-Related Announcements
Tonix Pharma Unveils Promising TNX-801 Vaccine Findings
Positive
Jul 10, 2025

On July 10, 2025, Tonix Pharmaceuticals announced new findings on their TNX-801 vaccine candidate at the Vaccine Congress 2025. TNX-801, a recombinant horsepox-derived vaccine, shows promise in providing durable immunity against mpox and smallpox with a single dose. The vaccine is significantly less virulent than traditional smallpox vaccines and is effective when administered subcutaneously, potentially reducing side effects. Preclinical studies demonstrated robust immune responses in various animal models, including immunocompromised subjects. This development positions TNX-801 as a critical tool for public health preparedness against orthopox viruses.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Tonix Pharma Publishes Phase 3 Trial Results
Positive
Jul 9, 2025

On July 9, 2025, Tonix Pharmaceuticals announced the publication of full results from its Phase 3 RESILIENT trial for TNX-102 SL in the journal Pain Medicine. This development could enhance the company’s positioning in the fibromyalgia treatment market by providing evidence of the product’s efficacy, potentially impacting stakeholders positively.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Tonix Pharma Publishes Study on TNX-1700 Efficacy
Positive
Jul 2, 2025

On July 2, 2025, Tonix Pharmaceuticals announced the publication of a collaborative study with Columbia University’s Medical School in the journal Cancer Cell. The study demonstrates that the murine version of their drug, TNX-1700, increased survival and decreased metastases in animal models of gastric cancer, suggesting potential for overcoming resistance to anti-PD-1 immunotherapy in gastric and other tumors.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Tonix Pharma Presents Data at Rheumatology Congress
Positive
Jun 16, 2025

On June 16, 2025, Tonix Pharmaceuticals presented data at the Annual European Congress of Rheumatology, highlighting their product TNX-102 SL, which targets non-restorative sleep and provides sustained pain reduction for fibromyalgia treatment. This presentation underscores Tonix’s ongoing efforts to enhance fibromyalgia treatment options, potentially strengthening their position in the pharmaceutical market and impacting stakeholders interested in innovative pain management solutions.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Tonix Pharma Appoints James Hunter to Board
Positive
Jun 13, 2025

On June 12, 2025, Tonix Pharmaceuticals appointed James Hunter to its Board of Directors. Mr. Hunter, who previously served as the company’s Executive Vice President of Commercial Operations and has extensive experience in commercial, sales, and marketing, was deemed not independent under NASDAQ standards. His appointment reflects the company’s strategic focus on leveraging his expertise for future growth.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Private Placements and Financing
Tonix Pharma Signs Major Sales Agreements for Funding
Positive
Jun 11, 2025

On June 11, 2025, Tonix Pharmaceuticals entered into a Sales Agreement with A.G.P./Alliance Global Partners to potentially sell up to $150 million in common stock, enhancing its financial flexibility. Additionally, Tonix signed a Purchase Agreement with Lincoln Park Capital Fund, allowing the sale of up to $75 million in newly issued shares, which could impact its market positioning by providing capital for general corporate purposes.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Tonix Pharma Begins Phase 2 OASIS Trial
Neutral
May 21, 2025

On May 21, 2025, Tonix Pharma announced the dosing of the first patient in the Phase 2 OASIS trial, which aims to evaluate the TNX-102 SL product candidate for reducing acute stress reaction and disorder. Sponsored by the University of North Carolina Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense, the trial will involve approximately 180 motor vehicle collision trauma survivors in the U.S., assessing the safety and efficacy of TNX-102 SL compared to a placebo.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Tonix Pharma Appoints New General Counsel and EVP
Neutral
May 14, 2025

On May 14, 2025, Tonix Pharmaceuticals announced the appointment of Joseph Hand as General Counsel and Executive Vice President of Operations, effective immediately. This strategic leadership change is expected to impact the company’s operations and potentially strengthen its industry positioning.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Executive/Board ChangesShareholder MeetingsStock Split
Tonix Pharma Approves Key Proposals at Shareholder Meeting
Neutral
May 8, 2025

On May 8, 2025, Tonix Pharma held its annual shareholder meeting where seven proposals were approved. Key decisions included the election of eight board members, ratification of EisnerAmper LLP as the accounting firm, and authorization for potential reverse stock splits. Additionally, shareholders approved amendments to the stock incentive plan, the 2025 Employee Stock Purchase Plan, and executive compensation, with a decision to hold executive compensation votes every three years.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 31, 2025